South Korea

GCCL Launches R&D Division to Bolster Biosimilar and Clinical Trial Analysis Services

Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis Including blockb...

 July 17, 2024 | News

Full-Life Technologies and SK Biopharmaceuticals Ink $571.5 Million Deal for Exclusive Rights to Radiopharmaceutical FL-091

Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, announced  that it has entered into a license agreement wit...

 July 17, 2024 | News

ADM Korea to Submit IND for Niclosamide-Based Combination Therapy for Prostate Cancer

IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. Niclosamide-based metab...

 July 12, 2024 | News

Genexine Merges with EPD Bio to Advance Targeted Protein Degradation Technology

Merger with EPD Bio, a biotech developing a target protein degrader (TPD) platform technology Jaehyun Choi, Ph.D. founder and CEO of EPD Bio, join...

 July 08, 2024 | News

South Korea's Genexine Merges with EPD Biotherapeutics to Enhance PROTAC Technology and Drug Pipeline

Genexine  a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the tre...

 July 05, 2024 | News

LOTTE BIOLOGICS Breaks Ground on Inaugural Plant at Songdo Bio Campus

LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheo...

 July 05, 2024 | News

South Korea's PharmAbcine Advances Novel nAMD Treatment PMC-403 to Key Phase 1 Milestones

PharmAbcine, a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the decision to advance ...

 July 02, 2024 | News

HiRO Acquires DeltaMed Solutions, Expands Across 10 Countries

Harvest Integrated Research Organization (HiRO), a full-service, boutique global CRO, is excited to announce its latest strategic move with the successful ...

 July 02, 2024 | News

Alteogen Subsidiary Altos Biologics Submits MAA to EMA for ALT-L9 Aflibercept Biosimilar

Alteogen Inc. announced that its subsidiary, Altos Biologics Inc. has submitted Marketing Authorization Application (MAA) to the European Medicines Ag...

 July 02, 2024 | News

CBC Group and Hasten Biopharmaceutical Acquire Asset Rights of 14 Branded Products from Celltrion in Major Pan-Asia Expansion

CBC Group (“CBC”), Asia’s largest healthcare-dedicated asset management firm headquartered in Singapore, announced  that its control...

 July 01, 2024 | News

South Korea Approves Reimbursement for Antengene's XPOVIO®, Expanding Access to Relapsed/Refractory Multiple Myeloma Treatment

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...

 June 27, 2024 | News

Hyundai Bioscience Develops Innovative Niclosamide-Based Multi-Treatment Drug for Mosquito-Borne Viral Infections

Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus...

 June 26, 2024 | News

GC Cell and Bifarma Forge Strategic Partnership to Pioneer Cell Therapy Market in Indonesia

GC Cell, a fully integrated cell and gene therapy pioneer, is proud to announce the establishment of an MOU for strategic partnership with Bifarma, a ...

 June 20, 2024 | News

GC Biopharma and Novel Pharma Receive FDA Fast Track Designation for Sanfilippo Syndrome Treatment GC1130A

GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA (Sanfili...

 June 11, 2024 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close